

Gossamer Bio Financing could provide up to $250 million, with much of the funding tied to seralutinib FDA milestones.
You can purchase shares of Gossamer Bio (NASDAQ:GOSS) through any online brokerage.
Other companies in Gossamer Bio’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Gossamer Bio has a consensus price target of $376.03.
The stock price for Gossamer Bio (NASDAQ: GOSS) is $10.38 last updated October 28, 2026 at 7:04 PM EDT.
There are no upcoming dividends for Gossamer Bio.
Gossamer Bio does not have any upcoming earnings scheduled.
There is no upcoming split for Gossamer Bio.
Gossamer Bio is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include...